ClinicalTrials.gg
Not yet recruitingNCT07938606Updated Nov 16, 2026

MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)

A Phase 1/2 interventional study of Emollient (moisturizer) and MG-K10 humanized monoclonal antibody injection in Atopic Dermatitis, sponsored by Shanghai Mabgeek Biotech.Co.Ltd. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Mabgeek Biotech.Co.Ltd · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
173rd of 190
24 · median 164
Started
2026
with 31 others
Phase 1/2
15 of 206
5 open now
Primary completion
2027-12
later than 59 of 81 live
Registered
205th of 206
by date
Lead sponsor
6 of 206
Shanghai Mabgeek Biotech.Co.Ltd

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 173rd largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2026, is one of 15 in phase 1/2, reaches primary completion later than 59 of the 81 other live ones, and was the 205th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis

Primary Objective:

To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).

Secondary Objectives:

To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Pharmacokinetics
  • Preliminary Efficacy
  • Pharmacodynamics
  • Immunogenicity
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥6 years and \<12 years (calculated based on the date of ICF signature), regardless of gender, with a baseline body weight ≥15 kg and \<60 kg.
  2. Diagnosed with atopic dermatitis (AD) according to the American Academy of Dermatology (AAD) consensus criteria (2014), with a history of AD or eczema diagnosed for ≥6 months prior to screening (with disease onset defined as the date of first symptom appearance).
  3. Inadequate response to topical medications within 12 months prior to screening, or medically unsuitable for topical medication therapy.
  4. Participants and/or their parents or legal guardians voluntarily provide written . For participants aged ≥6 years and \<8 years, signing an informed consent form is not required, but an assent form must be completed. Participants must be able to communicate effectively with the investigator and comply with protocol-required follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Unable to undergo subcutaneous injection
  2. Have other active skin diseases that may affect AD evaluation (such as psoriasis or lupus erythematosus);
  3. Have diseases that may require systemic or treatment;
  4. Patients with ocular diseases deemed unsuitable for enrollment by the investigator;
  5. Received allergen-specific immunotherapy within 6 months before dosing; Stopped all topical medications less than 2 weeks before dosing, including topical glucocorticoids, topical calcineurin inhibitors, antibiotic compound creams, topical TCM therapy;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    A:MG-K10 humanized monoclonal antibody injection

    Other: Emollient (moisturizer) · Drug: MG-K10 humanized monoclonal antibody injection

  • Experimental
    B:MG-K10 humanized monoclonal antibody injection

    Other: Emollient (moisturizer) · Drug: MG-K10 humanized monoclonal antibody injection

  • Experimental
    C:MG-K10 humanized monoclonal antibody injection

    Other: Emollient (moisturizer) · Drug: MG-K10 humanized monoclonal antibody injection

  • Experimental
    D:MG-K10 humanized monoclonal antibody injection

    Other: Emollient (moisturizer) · Drug: MG-K10 humanized monoclonal antibody injection

Interventions

  • OtherEmollient (moisturizer)

    Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

  • DrugMG-K10 humanized monoclonal antibody injection

    Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Incidence and severity of AEs, plus abnormality rates/severity of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG.

    Time frame: Up to Week 24

Secondary outcomes

  1. Percent of Participants with Investigator's Global Assessment (IGA) 0/1 and ≥2-Point Improvement

    Proportion achieving IGA score 0 or 1 AND ≥2-point reduction vs. baseline

    Time frame: Each assessment visit through Week 16

  2. Percent of Participants with ≥2-Point IGA Improvement

    Proportion with IGA reduction ≥2 points vs. baseline

    Time frame: Through Week 16

  3. Percent of Participants Achieving EASI-50, EASI-75, or EASI-90

    Proportion with ≥50%/75%/90% EASI reduction vs. baseline

    Time frame: Through Week 16

  4. Change in Lesion Body Surface Area (BSA)

    Change in lesion body surface area

    Time frame: Through Week 16

07

Study locations

1 site
  • Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938606
Lead sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Ma
Contact
bch_maleen2021@126.com
13601305676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion